San Diego, CA -- (SBWIRE) -- 03/19/2018 -- An investigation on behalf of investors of Sorrento Therapeutics Inc (NASDAQ:SRNE) shares over potential securities laws violations by Sorrento Therapeutics Inc and certain of its directors and officers in connection with certain financial statements was announced.

Investors who purchased shares of Sorrento Therapeutics Inc (NASDAQ:SRNE), have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm focuses on possible claims on behalf of purchasers of the securities of Sorrento Therapeutics Inc (NASDAQ: SRNE) concerning whether a series of statements by Sorrento Therapeutics Inc regarding its business, its prospects and its operations were materially false and misleading at the time they were made.

San Diego, CA based Sorrento Therapeutics, Inc., a clinical stage biotechnology company, primarily engages in the discovery and development of therapies focused on oncology and the treatment of chronic cancer pain worldwide. Sorrento Therapeutics Inc reported that its annual Total Revenue rose from $4.59 million in 2015 to $8.15 million in 2016 and that its Net Loss increased from $45.81 million in 2015 to $60.92 million in 2016.

Shares of Sorrento Therapeutics Inc (NASDAQ:SRNE) rose from $1.55 per share in June 2017 to as high as $10.65 per share on March 1, 2018.

On March 16, 2018, NASDAQ:SRNE shares closed at $7.75 per share.

Those who purchased shares of Sorrento Therapeutics Inc (NASDAQ:SRNE) have certain options and should contact the Shareholders Foundation.

Contact:
Shareholders Foundation, Inc.
Michael Daniels
3111 Camino Del Rio North - Suite 423
92108 San Diego
Phone: +1-(858)-779-1554
Fax: +1-(858)-605-5739
mail@shareholdersfoundation.com